Intra-operative administration of taurolidine reduces level of interleukin-1 beta rather than povidone-iodine in patients with colon, gastric, and pancreatic cancer. A clinical prospective randomised multicenter trial.
Completed
- Conditions
- Colon, gastric or pancreatic cancerCancer1. Malignant neoplasm of colon2. Malignant neoplasm of stomach3. Malignant neoplasm of pancreas
- Registration Number
- ISRCTN66478538
- Lead Sponsor
- Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
1. Open resection of colon, gastric, or pancreatic cancer
2. American Society of Anesthesiologists (ASA) I-III classification
3. Histopathological R0-resection
Exclusion Criteria
1. Complete ileus
2. ASA IV classification
3. Histopathological R1- or R2-resection
4. Unknown intra-operative metastasis, peritoneal carcinomatosis, intra-abdominal abscess, sepsis or clinically relevant organ failure
5. Apparent coagulopathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method